NEW YORK (GenomeWeb News) – GE Healthcare said this week it won a tender offer to exclusively provide next-generation sequencing services to a Karolinksa Institutet research group. The first clinical study using the technology will be directed at identifying mutations and genetic variants associated with metastatic breast cancer. Karolinska will provide patient tissue samples for the study. SeqWright Genomics Services, a subsidiary of GE Healthcare, will provide the sequencing services for analysis of the tissue samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.